Overview

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
Phase:
PHASE2
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Adalimumab
Azathioprine
Infliximab
Methotrexate
tocilizumab